Cystic Fibrosis
Overview
Plain-Language Overview
Cystic Fibrosis is a genetic disorder that primarily affects the lungs and digestive system. It causes the body to produce thick, sticky mucus that can clog airways and lead to frequent lung infections. This mucus also blocks the pancreas, preventing digestive enzymes from reaching the intestines and causing problems with nutrient absorption. People with Cystic Fibrosis often experience chronic coughing, difficulty breathing, and poor growth. The condition is caused by mutations in a gene that controls salt and water movement in and out of cells, leading to the buildup of thick secretions. Over time, lung damage and malnutrition can significantly impact health and quality of life.
Clinical Definition
Cystic Fibrosis is an autosomal recessive disorder caused by mutations in the CFTR gene, which encodes the cystic fibrosis transmembrane conductance regulator protein. This protein functions as a chloride channel critical for regulating salt and water transport across epithelial surfaces. Dysfunctional or absent CFTR leads to impaired chloride and bicarbonate secretion, resulting in dehydrated, viscous mucus in multiple organs. The hallmark pathology includes chronic pulmonary infections, bronchiectasis, and pancreatic insufficiency. The disease primarily affects the respiratory and gastrointestinal systems, causing progressive lung damage and malabsorption. Recurrent infections with organisms such as Pseudomonas aeruginosa and Staphylococcus aureus are common. The condition is a major cause of morbidity and mortality in affected individuals.
Inciting Event
Inheritance of biallelic pathogenic mutations in the CFTR gene initiates disease.
Newborns with CF often present after initial meconium ileus or failure to thrive.
Chronic colonization with pathogens like Pseudomonas aeruginosa triggers progressive lung damage.
Latency Period
Symptoms typically develop in early infancy or childhood but can present later in mild cases.
Pulmonary manifestations often progress over years to decades before severe respiratory failure.
Pancreatic insufficiency usually manifests within the first year of life.
Diagnostic Delay
Mild or atypical presentations with normal newborn screening can delay diagnosis.
Misattribution of symptoms to common respiratory infections or asthma leads to delayed recognition.
Lack of awareness of family history or subtle gastrointestinal symptoms may postpone testing.
Clinical Presentation
Signs & Symptoms
Chronic productive cough with thick, purulent sputum
Recurrent respiratory infections with wheezing and dyspnea
Failure to thrive and poor weight gain due to malabsorption
Steatorrhea and bulky, foul-smelling stools from pancreatic insufficiency
Salty-tasting skin reported by caregivers
History of Present Illness
Chronic productive cough with thick sputum and recurrent respiratory infections is common.
Failure to thrive and poor weight gain despite adequate caloric intake are typical.
Steatorrhea and bulky, foul-smelling stools indicate pancreatic insufficiency.
Nasal polyps and sinusitis frequently accompany respiratory symptoms.
Episodes of meconium ileus or distal intestinal obstruction syndrome may be reported.
Past Medical History
History of recurrent pneumonia or bronchiectasis is common.
Previous diagnosis of pancreatic insufficiency or malabsorption syndromes.
Newborn screening positive for elevated immunoreactive trypsinogen (IRT).
Prior hospitalizations for pulmonary exacerbations or respiratory failure.
Family History
Siblings or close relatives with cystic fibrosis or carrier status.
Family history of infertility in males due to congenital bilateral absence of the vas deferens.
Consanguineous parents increase risk of inheriting biallelic CFTR mutations.
Physical Exam Findings
Clubbing of the fingers due to chronic hypoxia and lung disease
Crackles and wheezing on lung auscultation from mucus obstruction and infection
Barrel chest from chronic lung hyperinflation
Nasal polyps visible on anterior rhinoscopy
Digital cyanosis in advanced pulmonary disease
Diagnostic Workup
Diagnostic Criteria
Diagnosis of cystic fibrosis is established by a combination of clinical features and confirmatory testing. The sweat chloride test is the gold standard, with values greater than 60 mmol/L considered diagnostic. Identification of two disease-causing mutations in the CFTR gene confirms the diagnosis. Newborn screening programs often detect elevated immunoreactive trypsinogen levels prompting further testing. Clinical presentation typically includes chronic respiratory symptoms and evidence of pancreatic insufficiency.
Pathophysiology
Key Mechanisms
Mutation in the CFTR gene causes defective chloride channel function leading to thick, viscous secretions in multiple organs.
Impaired chloride and bicarbonate secretion results in dehydrated mucus and impaired mucociliary clearance in the respiratory tract.
Viscous secretions cause airway obstruction, chronic infection, and inflammation leading to progressive lung damage.
Pancreatic duct obstruction by thick secretions causes exocrine pancreatic insufficiency and malabsorption.
Elevated sweat chloride due to defective reabsorption in sweat glands is a hallmark of CFTR dysfunction.
| Involvement | Details |
|---|---|
| Organs | Lungs are the primary site of disease with chronic infection, inflammation, and progressive respiratory failure. |
Pancreas is affected by exocrine insufficiency causing malabsorption and nutritional deficiencies. | |
Sweat glands produce abnormally salty sweat due to defective chloride reabsorption, used diagnostically in the sweat chloride test. | |
| Tissues | Respiratory epithelium is damaged by thick mucus and chronic infection leading to bronchiectasis. |
Pancreatic tissue undergoes fibrosis and exocrine insufficiency due to duct obstruction by thick secretions. | |
| Cells | Epithelial cells of the respiratory and gastrointestinal tracts produce defective CFTR protein leading to impaired chloride transport. |
Neutrophils accumulate in the lungs causing chronic inflammation and tissue damage in cystic fibrosis. | |
Goblet cells increase mucus production contributing to airway obstruction and infection. | |
| Chemical Mediators | Interleukin-8 (IL-8) is elevated in cystic fibrosis lungs and recruits neutrophils, perpetuating inflammation. |
Tumor necrosis factor-alpha (TNF-α) contributes to chronic airway inflammation and tissue injury. | |
Elastase released by neutrophils degrades lung tissue and impairs mucociliary clearance. |
Treatments
Pharmacological Treatments
CFTR modulators (e.g., ivacaftor, lumacaftor)
- Mechanism:
Enhance or correct the function of defective CFTR protein caused by CFTR gene mutations
- Side effects:
Headache
Elevated liver enzymes
Rash
- Clinical role:
First-line
Inhaled antibiotics (e.g., tobramycin, aztreonam)
- Mechanism:
Target chronic Pseudomonas aeruginosa lung infections to reduce bacterial load
- Side effects:
Ototoxicity
Bronchospasm
Cough
- Clinical role:
Long-term control
Pancreatic enzyme replacement therapy
- Mechanism:
Provide exogenous digestive enzymes to compensate for pancreatic insufficiency
- Side effects:
Abdominal pain
Fibrosing colonopathy (rare)
- Clinical role:
Supportive
Bronchodilators (e.g., albuterol)
- Mechanism:
Relax airway smooth muscle to improve airflow obstruction
- Side effects:
Tachycardia
Tremor
Hypokalemia
- Clinical role:
Adjunctive
Mucolytics (e.g., dornase alfa)
- Mechanism:
Break down extracellular DNA in mucus to reduce viscosity and improve clearance
- Side effects:
Pharyngitis
Voice alteration
Chest pain
- Clinical role:
Long-term control
Non-pharmacological Treatments
Chest physiotherapy and airway clearance techniques to mobilize and remove thick mucus from the lungs.
Nutritional support with high-calorie, high-fat diet to address malabsorption and maintain growth.
Regular exercise to improve pulmonary function and overall health.
Lung transplantation in end-stage respiratory failure refractory to medical management.
Prevention
Pharmacological Prevention
Inhaled mucolytics such as dornase alfa to reduce mucus viscosity
Chronic inhaled antibiotics (e.g., tobramycin) to prevent Pseudomonas colonization
Pancreatic enzyme replacement therapy to prevent malnutrition
CFTR modulators (e.g., ivacaftor) targeting specific CFTR mutations
Vitamin supplementation (A, D, E, K) to prevent fat-soluble vitamin deficiencies
Non-pharmacological Prevention
Chest physiotherapy and airway clearance techniques to mobilize mucus
Nutritional support with high-calorie, high-fat diet to maintain growth
Regular pulmonary function monitoring to detect early lung decline
Avoidance of tobacco smoke and respiratory irritants to reduce lung damage
Newborn screening for early diagnosis and intervention
Outcome & Complications
Complications
Bronchiectasis causing irreversible airway dilation and chronic infection
Respiratory failure from progressive lung damage
Pneumothorax due to ruptured subpleural blebs
Cor pulmonale from chronic hypoxic pulmonary vasoconstriction
Meconium ileus or distal intestinal obstruction syndrome causing bowel obstruction
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Cystic Fibrosis versus Primary Ciliary Dyskinesia
Cystic Fibrosis | Primary Ciliary Dyskinesia |
|---|---|
Autosomal recessive mutations in the CFTR gene affecting chloride channels | Usually autosomal recessive with mutations affecting ciliary structure |
Bronchiectasis predominantly in the upper lobes | Bronchiectasis predominantly in the middle and lower lung zones |
Chronic infections with Pseudomonas aeruginosa and Staphylococcus aureus | Frequent infections with Haemophilus influenzae and Staphylococcus aureus |
Elevated sweat chloride test and identification of CFTR mutations | Abnormal ciliary ultrastructure on electron microscopy |
Cystic Fibrosis versus Asthma
Cystic Fibrosis | Asthma |
|---|---|
Usually diagnosed in infancy or early childhood with chronic symptoms | Often presents in childhood or adolescence with episodic symptoms |
Progressive lung disease with irreversible bronchiectasis | Intermittent airway obstruction with reversible bronchospasm |
Normal IgE and eosinophil counts; sweat chloride elevated | Elevated serum IgE and eosinophilia common |
Requires airway clearance, pancreatic enzyme replacement, and CFTR modulators | Improves with bronchodilators and corticosteroids |
Cystic Fibrosis versus Bronchiectasis due to Immunodeficiency
Cystic Fibrosis | Bronchiectasis due to Immunodeficiency |
|---|---|
Normal immunoglobulin levels with defective chloride transport | Low immunoglobulin levels or defective antibody responses |
Chronic infections with Pseudomonas aeruginosa and Staphylococcus aureus | Recurrent infections with encapsulated bacteria like Streptococcus pneumoniae |
Elevated sweat chloride and CFTR gene mutations | Low serum immunoglobulins or abnormal vaccine response |
Cystic Fibrosis versus Allergic Bronchopulmonary Aspergillosis (ABPA)
Cystic Fibrosis | Allergic Bronchopulmonary Aspergillosis (ABPA) |
|---|---|
Normal or mildly elevated IgE without Aspergillus hypersensitivity | Elevated serum IgE and eosinophilia with positive Aspergillus skin test |
Diffuse bronchiectasis often involving upper lobes | Central bronchiectasis with mucus plugging |
Requires airway clearance, pancreatic enzyme replacement, and CFTR modulators | Improves with corticosteroids and antifungal therapy |
Cystic Fibrosis versus Shwachman-Diamond Syndrome
Cystic Fibrosis | Shwachman-Diamond Syndrome |
|---|---|
Autosomal recessive mutations in CFTR gene | Autosomal recessive mutations in SBDS gene |
Presents in infancy with exocrine pancreatic insufficiency and chronic lung disease | Presents in infancy with exocrine pancreatic insufficiency and bone marrow dysfunction |
Normal bone marrow function; sweat chloride elevated | Neutropenia and bone marrow failure common |
Elevated sweat chloride and CFTR mutations | Genetic testing showing SBDS mutations |